Trial Profile
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Hormones; Metformin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 24 Mar 2012 New source identified and integrated (European Clinical Trials Database record).
- 24 Nov 2011 New trial record